A recent study reveals that ADA2, previously known for its role in adenosine deamination, functions as an intracellular DNA-binding protein that controls TLR9 activation in plasmacytoid dendritic cells.
Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 ( TLR9 ) activation in response to nucleic acids, according to a recent study. ADA2, previously known for its role in catalyzing the deamination of adenosine to inosine, is revealed to function as an intracellular DNA-binding protein that controls TLR9 activation in plasmacytoid dendritic cells (pDCs).
This discovery provides insights into the functional differences among three classes of CpG oligodeoxynucleotides (ODNs) and suggests potential therapeutic strategies for modulating immune responses to infections and cancer. ADA2, a secreted protein with lower catalytic activity than ADA1, is highly expressed in monocytes, myeloid, and pDCs, and its concentrations increase in biological fluids upon immune cell activation. ADA2 deficiency (DADA2) is associated with systemic inflammation, vasculitis, early-onset stroke, cytopenia, and immunodeficiency, characterized by increased levels of TNF-α and type 1 interferon in patient plasma. The study suggests that extracellular ADA2 regulates myeloid cell polarization, TNF-α secretion, neutrophil activation, and IFN-β secretion by epithelial cells. The intracellular role of ADA2 in TLR9 activation was investigated, as TLR9 is a key receptor activated by dsDNA in response to infections and autoimmune diseases. The study found that ADA2 competes with TLR9 for binding to ssDNA, modulating the immune response. The research used a variety of methods, including cell isolation and culture, knock-down of ADA2 expression with siRNA, immunostaining, and confocal microscopy, to demonstrate that ADA2 binds to dsDNA and ssDNA, and that this binding is independent of ADA2's catalytic activity. The study also showed that ADA2 binds to ODNs in the lysosomes of macrophages, suggesting an intracellular role in regulating TLR9 activation
ADENOSINE DEAMINASE 2 TLR9 IMMUNE RESPONSE INFECTIONS CANCER
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stranger Than Fiction — a bold survey of the 20th-century novelGuided by enthusiasm, Edwin Frank’s study sidesteps the pitfalls of canonisation
Read more »
Netflix’s One Hundred Years of Solitude Breathes Life Into a Classic ‘Unfilmable’ NovelNetflix’s long-awaited adaptation of Gabriel García Márquez’s magnum opus captures the book's kinetic spirit.
Read more »
Novel single-cell genomics analysis approach provides direct insights into cell cycle and proliferationBy inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies key clones in cancer progression.
Read more »
Emily Atack cast in new drama based on 'addictive' novelThe Inbetweeners star has been cast in the Channel 5 thriller alongside Joanne Whalley and Rachel Shenton
Read more »
Phase one trial explores novel immunotherapy for breast cancerA groundbreaking phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been accepted for publication in JAMA Oncology.
Read more »
Emory University Hospital performs first U.S. implant of novel ventricular assist deviceOn Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ventricular assist device (VAD), which provides crucial care to patients with failing hearts.
Read more »